g.INSTITUT-MERIEUX

复旦大学附属肿瘤医院-梅里埃研究所实验室

共同目标:帮助肿瘤病人及临床医生应对疾病

共同使命:改善公众健康水平和实现个体化治疗;在体外诊断和免疫治疗方面满足医生和患者的需求;开展生物标志物研究:发现、鉴定并验证肿瘤相关标志物

里程碑

2006年8月18日,复旦大学附属肿瘤医院与法国生物梅里埃公司签订合作框架协议
2007年3月28日,复旦大学附属肿瘤医院与法国生物梅里埃公司签订协议,合作成立实验室,命名为复旦大学附属肿瘤医院-生物梅里埃实验室
2009年5月6日,复旦大学附属肿瘤医院-生物梅里埃实验室成立两周年纪念暨新实验室开幕
2010年5月13日,复旦大学附属肿瘤医院与法国梅里埃集团,即梅里埃研究所,重新签定五年合作协议,实验室更名为复旦大学附属肿瘤医院-梅里埃研究所实验室
2012年1月1日,”免疫与癌症”项目获得欧洲委员会第七框架协议计划为期四年的、贰佰万欧元的专项资助,第一个以中国实验室为主体申请获得第七框架协议计划资助的项目,旨在加强欧洲研究机构与中国合作方在复旦大学附属肿瘤医院-梅里埃研究所实验室开展科学研究,共同努力把该实验室建设成为亚洲在肿瘤预后领域的参考实验室。

复旦大学附属肿瘤医院-梅里埃研究所联合实验室的建立促进了临床医生和企业科研人员之间的密切交流与合作,充分发挥两者在公共健康及医学研究领域中的核心作用,切实有效地朝着满足病人和临床医生需求的方向发展,实现了克里斯多夫-梅里埃(Christophe MERIEUX)医生生前的愿望。实验室利用高通量生物芯片和各种分子生物学技术,及免疫学研究技术,开展肿瘤患者外周血基因表达谱研究,在复旦大学附属肿瘤医院和梅里埃集团的大力支持下,对结直肠癌和乳腺癌等的早期诊断及预后的免疫学、分子标记物进行了大量研究,希望在不久的将来,服务于公共健康领域。

发表的文献(不包括中文综述):

Identification and validation of a blood-based 18-gene expression signature in colorectal cancer. Clin Cancer Res. 2013;19(11):3039-49.

Gene expression analysis of peripheral blood cells reveals toll-like receptor pathway deregulation in colorectal cancer. PLoS One. 2013;8(5):e62870.

Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One. 2012; 7(9):e44398.

92-Gene molecular profiling in identification of cancer origin: a retrospective study in Chinese population and performance within different subgroups. PLoS One. 2012; 7(6):e39320.

PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy. Cancer Chemother Pharmacol. 2012; 70(5):637-44.

Investigation of variation in gene expression profiling of human blood by extended principle component analysis. PLoS One. 2011; 6(10):e26905.

Decrease in natural killer cell associated gene expression as a major characteristic of the immune status in the bloodstream of colorectal cancer patients. Cancer Biol Ther. 2011; 11(2):188-95.

Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy. Cancer Lett. 2011; 302(1):63-8.

Using peripheral blood mRNA signature to distinguish between breast cancer and benign breast disease in non-conclusive mammography patients. Cancer Biol Ther.2011; 10(12):1235-9.

Specific gene expression signature associated with development of autoimmune type-I diabetes using whole-blood microarray analysis. Genes Immun. 2010; 11(3):269-78.

The effect of colonoscopy on whole blood gene expression profile: an experimental investigation for colorectal cancer biomarker discovery. J Cancer Res Clin Oncol. 2014 PMID: 25306939.

MicroRNA-202-3p inhibits cell proliferation by targeting ADP-ribosylation factor-like 5A in human colorectal carcinoma. Clin Cancer Res. 2014; 20(5):1146-57.

The joint institute FuDan University Shanghai Cancer Center – Institut Mérieux laboratory (FDUSCC-IM) created in May 2010 is conducting ambitious research projects in oncology in China. This joint laboratory was created to promote interactions with hospital physicians and place public health as well as medicine at the heart of research activities. A dedicated research laboratory is currently running at the FuDan University Shanghai Cancer Center to develop and identify new biomarkers for early diagnosis of colorectal, lung and breast cancers.

Vision & Missions:

  • To reinforce public health and personalized medicine
  • To meet the needs of patients and clinicians, both in vitro diagnostics and in immunotherapy

Focus:

  • Oncology biomarker discovery and validation

Strengths:

  • Very close interaction with clinicians
  • Capacity for Molecular biology & Elisa
  • Immune response related

Milestone :

  • Term sheet:  Aug, 2006
  • 1st contract: Mar, 2007 – Mar, 2010
  • 2nd contract: Mar, 2010 – Mar, 2015
  • Immunocan Program: Jan, 2012 – Dec, 2015

Agenda France-China 50